Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Columbus,
Ohio43205

Purpose:

The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican)
administered to pediatric renal transplant recipients, and to provide additional safety
data.

Criteria:

Inclusion Criteria:
- Male and female patients no more than 16 years of age.
- Patients receiving a primary cadaveric or non-HLA identical living donor (related or
unrelated) renal transplant.
- The graft must be functional within 48 hours post transplantation.
Exclusion Criteria:
- Cold ischemia time greater than 40 hours.
- Patients who are recipients of multiple solid organ transplants, including dual and
en bloc kidneys, or who have previously received transplanted organs.
- Patients with panel reactive T cell antibodies of 50 % or higher at the last
assessment before transplantation.

NCT ID:

NCT00098241

Primary Contact:

Study DirectorNovartisNovartis

Backup Contact:

N/A

Location Contact:

Columbus, Ohio 43205United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.